Payment overview · 2025
General Payments
$386.31
18 reported records · 12 companies
Healthcare provider profile · identity verified
Gregory Todd Rainwater, MD
Allopathic & Osteopathic Physicians|Family Medicine · JASPER, GA · NPI 1972668200
Verified facts
What the public records show
CMS Open Payments records show Gregory Todd Rainwater, MD received $386.31 in general payments during 2025 across 18 reported records.
Corcept Therapeutics accounted for 16.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $62.74 | 16.2% | 2 | 2025 |
| Telix Pharmaceuticals | Unresolved — no canonical attribution shown | $54.95 | 14.2% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $54.35 | 14.1% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $46.41 | 12.0% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $42.99 | 11.1% | 2 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $19.02 | 4.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.71 | 4.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.70 | 4.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.68 | 4.8% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $18.18 | 4.7% | 1 | 2025 |
| Ferring Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.19 | 4.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.39 | 4.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $386.31 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $62.74 | 2 | 2025 |
Source payment records
|
|||||
| ILLUCCIX Normalized: illuccix |
Drug | Telix Pharmaceuticals | $54.95 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $54.35 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $46.41 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $26.91 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $26.91 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $19.02 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.71 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $18.71 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.71 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.70 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.70 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $18.68 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $18.18 | 1 | 2025 |
Source payment records
|
|||||
| EUFLEXXA Normalized: euflexxa |
Device | Ferring Pharmaceuticals Inc. | $16.19 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $16.08 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.39 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 60 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
51 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
71 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
79 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
60 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
46 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 584 | 162 |
| Atorvastatin Calcium | Atorvastatin Calcium | 487 | 143 |
| Amlodipine Besylate | Amlodipine Besylate | 450 | 127 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 353 | 96 |
| Lisinopril | Lisinopril | 352 | 103 |
| Alprazolam | Alprazolam | 284 | 47 |
| Omeprazole | Omeprazole | 264 | 82 |
| Gabapentin | Gabapentin | 263 | 85 |
| Tramadol Hcl | Tramadol Hcl | 261 | 59 |
| Methylprednisolone | Methylprednisolone | 229 | 189 |
| Losartan Potassium | Losartan Potassium | 227 | 75 |
| Pantoprazole Sodium | Pantoprazole Sodium | 205 | 70 |
| Tamsulosin Hcl | Tamsulosin Hcl | 205 | 60 |
| Fluoxetine Hcl | Fluoxetine Hcl | 180 | 37 |
| Metformin Hcl | Metformin Hcl | 155 | 46 |
| Trazodone Hcl | Trazodone Hcl | 155 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 153 | 49 |
| Clonazepam | Clonazepam | 144 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 140 | 34 |
| Furosemide | Furosemide | 139 | 46 |
| Simvastatin | Simvastatin | 134 | 38 |
| Carvedilol | Carvedilol | 118 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 118 | 37 |
| Escitalopram Oxalate | Escitalopram Oxalate | 115 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 113 | 42 |
| Sertraline Hcl | Sertraline Hcl | 108 | 32 |
| Zolpidem Tartrate | Zolpidem Tartrate | 108 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 105 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 100 | 32 |
| Glimepiride | Glimepiride | 100 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 98 | 27 |
| Lorazepam | Lorazepam | 98 | 26 |
| Atenolol | Atenolol | 96 | 28 |
| Allopurinol | Allopurinol | 95 | 36 |
| Famotidine | Famotidine | 95 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 93 | 31 |
| Diclofenac Sodium | Diclofenac Sodium | 91 | 48 |
| Meloxicam | Meloxicam | 91 | 33 |
| Montelukast Sodium | Montelukast Sodium | 87 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 84 | 27 |
| Potassium Chloride | Potassium Chloride | 80 | 19 |
| Mounjaro | Tirzepatide | 79 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 78 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 78 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 77 | 37 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 71 | 14 |
| Metformin Hcl Er | Metformin Hcl | 70 | 22 |
| Bupropion Xl | Bupropion Hcl | 69 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 69 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 68 | 20 |
| Nifedipine Er | Nifedipine | 66 | 18 |
| Ezetimibe | Ezetimibe | 64 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 63 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 63 | 15 |
| Ondansetron Odt | Ondansetron | 60 | 32 |
| Ozempic | Semaglutide | 60 | 14 |
| Pregabalin | Pregabalin | 58 | 16 |
| Baclofen | Baclofen | 56 | 21 |
| Celecoxib | Celecoxib | 54 | 31 |
| Januvia | Sitagliptin Phosphate | 53 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 53 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 51 | 13 |
| Synthroid | Levothyroxine Sodium | 51 | 14 |
| Memantine Hcl | Memantine Hcl | 49 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 49 | 14 |
| Valacyclovir | Valacyclovir Hcl | 49 | 24 |
| Temazepam | Temazepam | 48 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 47 | 11 |
| Irbesartan | Irbesartan | 47 | 11 |
| Alendronate Sodium | Alendronate Sodium | 46 | suppressed |
| Eliquis | Apixaban | 46 | 17 |
| Valsartan | Valsartan | 46 | 13 |
| Finasteride | Finasteride | 44 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 44 | 24 |
| Doxepin Hcl | Doxepin Hcl | 43 | 11 |
| Aripiprazole | Aripiprazole | 42 | 16 |
| Xarelto | Rivaroxaban | 42 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 41 | 36 |
| Hydralazine Hcl | Hydralazine Hcl | 40 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 40 | suppressed |
| Dexamethasone | Dexamethasone | 39 | 26 |
| Mirtazapine | Mirtazapine | 39 | 12 |
| Azithromycin | Azithromycin | 38 | 35 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 38 | 11 |
| Estradiol | Estradiol | 37 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 36 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 34 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 34 | suppressed |
| Lovastatin | Lovastatin | 34 | suppressed |
| Torsemide | Torsemide | 34 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | 11 |
| Clonidine Hcl | Clonidine Hcl | 33 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 33 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 33 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 31 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 30 | suppressed |
| Amoxicillin | Amoxicillin | 29 | 26 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 26 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Diazepam | Diazepam | 28 | 11 |
| Fluconazole | Fluconazole | 28 | 19 |
| Glipizide Er | Glipizide | 28 | suppressed |
| Jardiance | Empagliflozin | 28 | suppressed |
| Repatha Sureclick | Evolocumab | 28 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 27 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 27 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 27 | suppressed |
| Carisoprodol | Carisoprodol | 26 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 26 | 11 |
| Rabeprazole Sodium | Rabeprazole Sodium | 26 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 26 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 25 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 24 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | 11 |
| Ipratropium Bromide | Ipratropium Bromide | 24 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 23 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Eszopiclone | Eszopiclone | 22 | suppressed |
| Linzess | Linaclotide | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Fentanyl | Fentanyl | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | 18 |
| Nitroglycerin | Nitroglycerin | 21 | 14 |
| Repaglinide | Repaglinide | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 19 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 19 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Etodolac | Etodolac | 19 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 19 | suppressed |
| Dutasteride | Dutasteride | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Testosterone | Testosterone | 18 | suppressed |
| Flurbiprofen | Flurbiprofen | 17 | suppressed |
| Nabumetone | Nabumetone | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 17 | suppressed |
| Cefdinir | Cefdinir | 16 | 13 |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | 11 |
| Glipizide | Glipizide | 15 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 14 |
| Nystatin | Nystatin | 15 | 11 |
| Scopolamine | Scopolamine | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Silodosin | Silodosin | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Betaxolol Hcl | Betaxolol Hcl | 11 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Prednisone | Prednisone | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $386.31 · 18 records | Corcept Therapeutics | ABRYSVO, AREXVY, CAPLYTA, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, EUFLEXXA, Heplisav-B, ILLUCCIX, JARDIANCE, Korlym, Ozempic, PREVNAR 20, QULIPTA, SHINGRIX, UBRELVY, VRAYLAR | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error